Sphingotec's new biomarker bio-ADM identifies ICU patients who need immediate organ s
Diagnostics company SphingoTec GmbH today announced a publication in Critical Care1 with data on 2,000 ICU patients demonstrating that sphingotec's proprietary biomarker bio-ADM (Bioactive Adrenomedullin) not only identifies high-risk patients for septic shock at admission but also identifies patients in the general ICU patient population who require immediate life-saving therapeutic intervention.
More... |
All times are GMT -7. The time now is 02:55 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021